RenovoRx Inc Cash Flow Conversion Efficiency
RenovoRx Inc cash flow conversion efficiency. Based on the latest financial reports, RenovoRx Inc (RNXT) has a cash flow conversion efficiency ratio of -0.319x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.87 Million) by net assets ($8.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of RenovoRx Inc (2019–2025)
Cash flow conversion efficiency of RenovoRx Inc from 2019 to 2025. This chart illustrates how RenovoRx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View RenovoRx Inc share price for real-time trading data and today's change.
RenovoRx Inc Cash Flow Conversion Ratio Explained
RenovoRx Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
RenovoRx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RenovoRx Inc ranked by their cash flow conversion efficiency. Also see RNXT market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Maan Aluminium Limited
NSE:MAANALU
|
0.076x |
|
NFON AG
XETRA:NFN
|
0.024x |
|
Crown Confectionery Co Ltd
KO:264900
|
0.048x |
|
ActRO Co. Ltd
KQ:290740
|
0.101x |
|
Cassava Sciences Inc
NASDAQ:SAVA
|
-0.130x |
|
Taiwan Pelican Express Co Ltd
TW:2642
|
0.025x |
|
Citius Oncology, Inc.
NASDAQ:CTOR
|
-0.071x |
|
MS Autotech Co.Ltd
KQ:123040
|
0.004x |
Annual Cash Flow Conversion Efficiency for RenovoRx Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of RenovoRx Inc from 2019 to 2025. Review RenovoRx Inc (RNXT) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.42 Million | $-10.97 Million | -2.024x | +0.68% |
| 2024-12-31 | $4.48 Million | $-9.12 Million | -2.038x | -159.59% |
| 2023-12-31 | $-3.00 Million | $-10.26 Million | 3.419x | +339.17% |
| 2022-12-31 | $6.16 Million | $-8.81 Million | -1.430x | -270.92% |
| 2021-12-31 | $15.35 Million | $-5.92 Million | -0.385x | -260.12% |
| 2020-12-31 | $-14.66 Million | $-3.53 Million | 0.241x | +110.53% |
| 2019-12-31 | $1.47 Million | $-3.35 Million | -2.287x | -- |
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded i… Read more